【 周期素依賴激酶1抗體】齊一生科技（上海）有限公司感謝您的查閱與咨詢！期待與您的真誠合作!

低價(jià)格現(xiàn)貨供應(yīng),歡迎前來選購。齊一生物銷售：021－6034 8496；181214 53965；173021 04490網(wǎng)站：www.qiyibio.com【 周期素依賴激酶1抗體】

9237932  Syringe, 100µl              CNY                             周期素依賴激酶1抗體

9240663  Nut, Flangeless,1/4-28, Black, AP        CNY                           

9240634  Power Supply, Main PCB, Aztec, AP196/98         CNY                           

9240630  Power Supply, 5VDC 1.5 AMP, AP96          CNY                           

9240593  Unload Valve, Pump, Pressure, AP196/98            CNY                           

9240562  Fuse, PCB, 315, Eppendorf, AP196/98        CNY                           

9240536  Motor Assy, SiNug, 17, All, AP96/196         CNY                           

9240514  CD R/W, AP196/98              CNY                           

9240504  PC-104, AP98        CNY                           

9240346  Autopure, Full Agreement      "Repair service delivery: onsite

Service response time (repair): 48 hours/2 business days

Periodic inspection/maintenance: yes, 1/agreement year

Inspection/maintenance delivery: onsite

Cost coverage for repair parts: yes, included

Cost coverage for labor: yes, included

Cost coverage for travel: yes, included

Replacement system (Loaner) provision: not included

Transportation cost coverage: not applicable"      CNY                           

9240098  Re-Installation, BR EZ1  The Re-Installation, BR EZ1 facilitates quick implementation of system back into lab routine by minimizing  instrument set-up phase. It covers hardware ａnd software check of instrument ａnd provides user with operator refesher overview.  Re-installation includes labor ａnd travel costs. Re-installation performance process is documented on a GMP/GLP-compliant Field Service document.     CNY                           

9239852  Foot bumpers,  v2.0 (4)             CNY                           

9019944  Cable, P-axis, wires, 8 ch. , C18          CNY                           

9238880  Bearings up. & low, BS96            CNY                           

9238836  BioSprint96, Basic Agreement, no PM   "Repair service delivery: onsite

Service response time (repair): 5 business days

Periodic inspection/maintenance: not included

Inspection/maintenance delivery: not applicable

Cost coverage for Repair Parts : yes, full coverage

Cost coverage for labor: yes, full coverage

Cost coverage for travel: yes, full coverage

Replacement system (Loaner) provision: not applicable

Transportation cost coverage: not applicable"      CNY                           

9241211  Full Agreement Depot Repair, DML2000, 1y "The Full Agreement Depot Repair, DML2000 provides full service coverage for the DML 2000 luminometer. The service is conducted as an instrument exchange service.

All shipping, labor ａnd repair part costs related to an instrument exchange are included for 1 year. Instrument exchange time is 2 - 3 working days."       CNY                           

9241191  Magnet, tool, QX          CNY                             周期素依賴激酶1抗體

9238825  Spare bucket for plate rotor          CNY                           

9238815  Rect. carrier for 12 tubes 10 ml w/ cap              CNY                           

9019472  TAPE SPACER CLEAR GS          CNY                           

9019464  UV tube, Cxx         CNY                           

9243650  Comprehen Valid., EZ1/QIAcube/QIAsymph       """The Comprehensive Validation Support plan specific to a laboratory＇s needs will incorporate all of the requirements for the internal validation guidelines from the FBI＇s Quality Assurance Standards (QAS).

The Comprehensive Validation Support service includes all travel ａnd labor charges for up to 20 days by the QIAGEN Validation Team. Typically, one week will be required to extract, quantify, ａnd amplify the validation study samples ａnd may require multiple individuals. Usually, two weeks is required to analyze the data ａnd one week to write the final report. The expected time period to complete the Comprehensive Validation is six weeks. The actual time may vary depending on resource availability, including laboratory time dedicated to validation activities.

Lab Work – The QIAGEN specialist(s) will travel to the laboratory to conduct the on-site validation lab work. The QIAGEN specialist team will perform ａnd complete all extractions, quantifications, amplfications, ａnd capillary electrophoresis. The laboratory is responsible for providing systems/protocols that may be needed (generally laboratory SOPs, ex. interpretation guidelines). Additionally, the laboratory staff may be required to provide additional data needed for interpretation (ex. quantification/amplification/CE results) during the data review phase of the validation.

Once the final scope of the validation is determined, QIAGEN will provide a quote for all consumables required for the validation.  Non-QIAGEN chemistry ａnd accessories are not included ａnd should  be purchased to cover the validation experimental design including qPCR, STR, NIST standards, required samples types (blood, semen, buccal samples) ａnd required substrates (swabs, materials, etc).   The Customer is expected to have all materials on-hand 1 week prior to the validation start date.

Data Analysis – The Comprehensive Validation Support plan encompasses data collection (quants, amps, CE) during the on-site visit. The laboratory may be responsible for sharing (typically electronically via e-mail) any validation data requested after the on-site visit. A QIAGEN specialist will complete all of the data analysis produced from the validation study design. This includes qPCR (quant) ａnd STR (amp) analysis ａnd linkage to starting samples.

Validation data CD/flashdrive – QIAGEN will review the validation data ａnd draft a validation summary document, ensuring compliance with the FBI＇s QAS requirements/standards. QIAGEN will send validation data in an electronic format (email/CD/flashdrive) to the laboratory. The laboratory is responsible for final compilation, any format change preferences, review ａnd signoff of the validation report. The documentation provided by QIAGEN will aide in demonstrating compliance with all accreditation guidelines during laboratory audits. Should a hard copy of the validation study be preferred, the laboratory is required to specify prior to the onset of the validation.

Post-validation QIAGEN-to-Laboratory Transfer – Following completion of the validation ａnd generation of the draft validation summary document, a designated member of the QIAGEN validation team will review the validation with the Lab Manager ａnd the Technical Leader. Following sign off on the validation report, training of the laboratory DNA staff will occur. Refer to the Post-validation Competency Training for additional information. """   CNY                           

9237333  Install, BR plus 3 integr. w. scheduling  Installation ａnd training, BioRobot System including three approved integration devices with scheduling CNY                           

9237328  Upgrade, BR & 2 ext. devices w. sched.      Upgrade BioRobot with two approved integration devices using scheduling software  CNY                           

9237173  Shield, V-housing          CNY                           

9233208  Tubing, liquid system 2.5/1.5        CNY                           

9237155  V-Housing with Sample Needle            CNY                           

9237150  Heater Top             CNY                           

9016151  #App. Package, M48, Pathology          CNY                           

QY-x1172       人乳腺導(dǎo)管癌細(xì)胞MDA-MB-453                                         

QY-x1173       人乳腺細(xì)胞HBL-100                                      

QY-x1174       人乳腺癌細(xì)胞BCaP-37                                   

QY-x1175       人乳腺癌細(xì)胞LCC1                                       

QY-x1176       人乳腺癌細(xì)胞MX-1                                       

QY-x1177       人乳腺管癌細(xì)胞T47D                                    

QY-x1178       人乳腺癌細(xì)胞SK-BR-3                                     周期素依賴激酶1抗體

QY-x1179       人乳腺癌細(xì)胞4T1                                   

QY-x1180       人乳腺癌細(xì)胞HCC1937                                         

QY-x1181       人乳腺導(dǎo)管癌細(xì)胞HCC38                                     

QY-x1182       人乳腺癌細(xì)胞Hs-578T                                   

QY-x1183       人乳腺癌Tamoxifen耐藥株LCC2                                        

QY-x1184       人乳腺癌抗雌激素耐藥株LCC9                                    

QY-x1185       人乳腺癌阿霉素耐藥細(xì)胞株MCF/Adr                                         

QY-x1186       人乳腺癌細(xì)胞BT-549                                     

QY-x1187       人乳腺導(dǎo)管瘤細(xì)胞BT-474                                     

QY-x1188       人乳腺癌細(xì)胞MB-271                                    

QY-x1189       人乳腺癌細(xì)胞ER-30                                      

QY-x1190       人乳腺癌細(xì)胞M453                                       

QY-x1191       人乳腺浸潤性導(dǎo)管癌旁皮膚細(xì)胞CCD-1095Sk                                   

QY-x1192       人乳腺細(xì)胞HBL-100                                      

QY-x1193       人乳腺導(dǎo)管瘤細(xì)胞UACC812                                        

QY-x1194       人乳腺癌細(xì)胞系1590                                     

QY-x1195       人卵巢癌細(xì)胞A2780                                      

QY-x1196       人卵巢癌細(xì)胞Sw626                                       周期素依賴激酶1抗體

QY-x1197       人卵巢癌順鉑耐藥株COC1/CDDP                                       

QY-x1198       人卵巢癌紫杉醇耐藥株A2780/Taxol                                    

QY-x1199       人卵巢癌細(xì)胞系Anglne                                         

QY-x1200       人卵巢癌細(xì)胞OVCaR-3                                         

QY-x1201       人卵巢癌細(xì)胞Caov-3                                     

QY-x1202       人卵巢癌細(xì)胞HO-8910